Cargando…
Case report: Therapy adherence, MTTP variants, and course of atheroma in two patients with HoFH on low-dose, long-term lomitapide therapy
Background: Homozygous familial hypercholesterolemia (HoFH) is a rare and devastating genetic condition characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) leading to an increased risk of premature atherosclerosis. Patients with Homozygous familial hypercholeste...
Autores principales: | Kayikcioglu, Meral, Ozkan, Hasan Selcuk, Yagmur, Burcu, Bayraktaroglu, Selen, Vardarli, Asli Tetik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845397/ https://www.ncbi.nlm.nih.gov/pubmed/36685950 http://dx.doi.org/10.3389/fgene.2022.1087089 |
Ejemplares similares
-
Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting
por: Mahzari, Moeber, et al.
Publicado: (2021) -
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey
por: D’Erasmo, Laura, et al.
Publicado: (2021) -
Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey
por: Walzer, S, et al.
Publicado: (2013) -
Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study
por: Nohara, Atsushi, et al.
Publicado: (2019) -
Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)